DejanJuricMD

Oncology • Boston, MA

Breast Cancer, Clinical Pharmacology

Director, Termeer Center for Targeted Therapies, Massachusetts General Hospital

Join to view full profile

Dr. Juric is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Juric's full profile

Already have an account?

Office
55 Fruit St
Boston, MA 02114
Phone+1 617-726-6500

Fax+1 617-724-1079

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2009 - 2012
Massachusetts General HospitalResidency, Internal Medicine, 2007 - 2009
University of Zagreb Faculty of MedicineClass of 2001

Certifications & Licensure

MA State Medical License 2011 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Start of enrollment: 2012 Mar 01
Completed
Phase 1
Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer Start of enrollment: 2012 Sep 21
Completed
Phase 1
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer Start of enrollment: 2013 Apr 01
Active, not recruiting
Phase 1
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22
Active, not recruiting
Phase 1, Phase 2
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2014 Aug 07
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

137 citations
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre...
Hope S Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruiz-Borrego
The Lancet. Oncology. 2024-12-01
Immune responses in checkpoint myocarditis across heart, blood and tumour.
Steven M Blum, Daniel A Zlotoff, Neal P Smith, Isabela J Kernin, Swetha Ramesh
Nature. 2024-12-01
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advance...
Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, Andrés Cervantes, Valentina Gambardella
Journal of Clinical Oncology. 2024-11-20

Lectures

Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-)...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Evaluating Inavolisib vs Alpelisib plus Fulvestrant for Hormone Receptor-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast CancerSeptember 24th, 2024
Remembering JoséMarch 30th, 2021
How Targeted Therapies Are Changing the Breast Cancer Treatment LandscapeMarch 26th, 2021
Join now to see all